Underwriters over-allotment is an additional 1.8M shares.
Net proceeds will be used for the development of clinical trials, regulatory, research and development expenses, for working capital and general corporate purposes.
Closing date is December 17.
Shares are down 6% premarket.
Previously: Marinus Pharma launches 12M-share stock offering; shares down 7% after hours (Dec. 11)
Subscribe for full text news in your inbox